AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11605932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia (10 microg intrathecal sufentanil with or without 2.0 mg bupivacaine, n = 1,071)
Number of subjects: 2183
Study 11605932 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (10 microg epidural sufentanil and 12.5-25.0 mg bupivacaine, n = 1,112)
Number of subjects: 2183
Study 11605932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia
Number of subjects: 2183
Study 11605932 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 2183
Study 11605932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural and epidural analgesia
Number of subjects: 2183
Study 10921016 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cyclophosphamide (CTX) 300 mg/m2, vincristine (VCR) 1.4 mg/m2, adriamycin (ADM) 50 mg/m2, d1; cisplatin (PDD) 20 mg/m2, d1-5, for 4 cycles, followed by oral ftorafur (FT-207) 600-900 mg/d for 1 year
Number of subjects: 70
Study 10921016 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 70
Study 10921016 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for stage III patients
Number of subjects: 70
Study 10921016 — intervention group
Group type: COMPARATOR
Intervention: Surgery only for stage III patients
Number of subjects: 70
Study 10921016 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for stage I-II patients
Number of subjects: 70
Study 10921016 — intervention group
Group type: COMPARATOR
Intervention: Surgery only for stage I-II patients
Number of subjects: 70
Study 8273654 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (contrast-enhanced MR imaging)
Number of subjects: 60
Study 8273654 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced MR imaging
Number of subjects: 60
Study 8273654 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all sequences (enhanced and unenhanced)
Number of subjects: 60
Study 8273654 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine
Number of subjects: 60
Study 2511801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for 7 days
Number of subjects: 13
Study 2511801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 600 mg once daily for 7 days
Number of subjects: 13
Study 2511801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 800 mg once daily for 7 days
Number of subjects: 13
Study 2511801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin (any dosage)
Number of subjects: 13
Study 2511801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 800 mg
Number of subjects: 13
Study 2511801 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 13
Study 337916 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug regimen (cyclophosphamide, methotrexate, fluorouracil)
Number of subjects: 72
Study 337916 — intervention group
Group type: COMPARATOR
Intervention: Five-drug regimen (vincristine sulfate, prednisone, cyclophosphamide, methotrexate, fluorouracil)
Number of subjects: 72
Study 337916 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-drug regimen after progression of disease
Number of subjects: 72
Study 31235195 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal Function Exercises (VFEs) + Vocal Hygiene counseling (VH), n=6
Number of subjects: 10
Study 31235195 — intervention group
Group type: COMPARATOR
Intervention: Vocal Hygiene counseling (VH), n=4
Number of subjects: 10
Study 31046941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitch-earcons
Number of subjects: 0
Study 31046941 — intervention group
Group type: COMPARATOR
Intervention: Timbre-earcons
Number of subjects: 0
Study 26869596 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive dynamic wrist and hand orthosis combined with computerised gaming exercises
Number of subjects: 20
Study 26869596 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercises from an exercise book
Number of subjects: 20
Study 25899102 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (10 mg.d(‐1))
Number of subjects: 29
Study 25899102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 25035069 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC 50/250 μg Rotacaps/Rotahaler (S)
Number of subjects: 36
Study 25035069 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC 50/250 μg Rotacaps/Rotahaler (L)
Number of subjects: 36
Study 25035069 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC 50/100 μg Rotacaps/Rotahaler (L)
Number of subjects: 36
Study 25035069 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC at both doses and via both inhalers
Number of subjects: 36
Study 22915299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 1.25 mg
Number of subjects: 22
Study 22915299 — intervention group
Group type: COMPARATOR
Intervention: Low-fluence photodynamic therapy (L-PDT) with verteporfin (300 mW/cm² for 83 s, 25 J/cm²)
Number of subjects: 22
Study 22915299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 22
Study 22915299 — intervention group
Group type: COMPARATOR
Intervention: Low-fluence photodynamic therapy (L-PDT)
Number of subjects: 22
Study 19306148 — intervention group
Group type: EXPERIMENTAL
Intervention: FearFighter (FF)
Number of subjects: 62
Study 19306148 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-led exposure
Number of subjects: 62
Study 19306148 — intervention group
Group type: COMPARATOR
Intervention: Computed-aided relaxation
Number of subjects: 62
Study 17596474 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide treatment
Number of subjects: 0
Study 17596474 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy
Number of subjects: 0
Study 15049746 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine abusers
Number of subjects: 144
Study 15049746 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin abusers
Number of subjects: 144
Study 15049746 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol abusers
Number of subjects: 144
Study 15049746 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin abusers (abstinent)
Number of subjects: 144
Study 15049746 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine abusers (abstinent)
Number of subjects: 144
Study 15049746 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol abusers (abstinent)
Number of subjects: 144
Study 11282168 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell responses specific for synapsin
Number of subjects: 2
Study 11282168 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term T cell lines specific for synapsin
Number of subjects: 2
Study 9290271 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based hypertension control program including blood pressure screening, health education, and follow-up by trained volunteers.
Number of subjects: 897
Study 9290271 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based hypertension control program targeting hypertensive subjects.
Number of subjects: 897
Study 9290271 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 897
Study 7931475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 131
Study 7931475 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 131
Study 3197711 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitogen stimulation assay
Number of subjects: 0
Study 3197711 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled studies using animal lymphocytes or paired human samples
Number of subjects: 0
Study 29797907 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongdu Tiaoshen needles therapy
Number of subjects: 60
Study 29797907 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 60
Study 29797907 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 26975954 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily for 2 weeks)
Number of subjects: 80
Study 26975954 — intervention group
Group type: COMPARATOR
Intervention: Control (no agent)
Number of subjects: 80
Study 26291564 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 120
Study 26291564 — intervention group
Group type: COMPARATOR
Intervention: Bipolar transurethral resection of the prostate (TURPb)
Number of subjects: 120
Study 23902782 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1500 mg/d during pregnancy)
Number of subjects: 68
Study 23902782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 21903984 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 63
Study 21903984 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 63
Study 18239086 — intervention group
Group type: EXPERIMENTAL
Intervention: R-HDS (rituximab-supplemented high-dose sequential chemotherapy with autografting)
Number of subjects: 136
Study 18239086 — intervention group
Group type: COMPARATOR
Intervention: CHOP-R (6 courses of CHOP followed by rituximab)
Number of subjects: 136
Study 18239086 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage R-HDS after CHOP-R failure
Number of subjects: 136
Study 16639669 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser scanning tomography (LST) and nerve fibre polarimetry measurements in eyes with large cups
Number of subjects: 117
Study 16639669 — intervention group
Group type: COMPARATOR
Intervention: Laser scanning tomography (LST) and nerve fibre polarimetry measurements in normal eyes
Number of subjects: 117
Study 16639669 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT and GDx measurements in eyes with large cups
Number of subjects: 117
Study 12748567 — intervention group
Group type: EXPERIMENTAL
Intervention: Canalith repositioning maneuver (CRM)
Number of subjects: 47
Study 12748567 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CRM and vestibular rehabilitation (VR)
Number of subjects: 47
Study 12748567 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 47
Study 15135713 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0
Study 10450715 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (10-40 mg/d) with possible addition of enalapril (5-20 mg/d) and/or hydrochlorothiazide (12.5-25.0 mg/d)
Number of subjects: 808
Study 10450715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 808
Study 8524699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine monotherapy
Number of subjects: 47
Study 8524699 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with nifedipine and metoprolol
Number of subjects: 47
Study 8524699 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 47
Study 2331067 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal airway
Number of subjects: 203
Study 2331067 — intervention group
Group type: COMPARATOR
Intervention: Gauze bite-block
Number of subjects: 203
Study 2331067 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood noted on airway instruments
Number of subjects: 203
Study 2331067 — intervention group
Group type: EXPERIMENTAL
Intervention: No blood noted on airway instruments
Number of subjects: 203
Study 2331067 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation by an anesthesia resident with less than 1 yr experience
Number of subjects: 203
Study 487688 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol, 50 mg daily
Number of subjects: 19
Study 487688 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, 80 mg daily
Number of subjects: 19
Study 487688 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, 160 mg daily
Number of subjects: 19
Study 487688 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, 640 mg daily
Number of subjects: 19
Study 487688 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol, 200 mg daily
Number of subjects: 19
Study 487688 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol, 400 mg daily
Number of subjects: 19
Study 487688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30924169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Number of subjects: 76
Study 30924169 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study 27997267 — intervention group
Group type: EXPERIMENTAL
Intervention: RF Group (n = 16)
Number of subjects: 46
Study 27997267 — intervention group
Group type: EXPERIMENTAL
Intervention: RF and LLLT Group (n = 15)
Number of subjects: 46
Study 27997267 — intervention group
Group type: COMPARATOR
Intervention: Control Group (n = 15)
Number of subjects: 46
Study 25832578 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuebinger-Intensiv-Programm für Eltern (Tipe)
Number of subjects: 0
Study 25832578 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 0
Study 24227718 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal imaging combined with behavioral measurements
Number of subjects: 0
Study 21362276 — intervention group
Group type: EXPERIMENTAL
Intervention: PCPS-MNC-CM from DE group
Number of subjects: 25
Study 21362276 — intervention group
Group type: COMPARATOR
Intervention: PCPS-MNC-CM from EU group
Number of subjects: 25
Study 20011596 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1-infected partners with HSV-2-seropositive status
Number of subjects: 416
Study 20011596 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of STI in partner
Number of subjects: 416
Study 20011596 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected sex
Number of subjects: 416
Study 20011596 — intervention group
Group type: EXPERIMENTAL
Intervention: Low education
Number of subjects: 416
Study 20011596 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV-2 status in HIV-1-uninfected participants
Number of subjects: 416
Study 16970952 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate
Number of subjects: 351
Study 16970952 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 351
Study 14982562 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 60 mg ml(-1)
Number of subjects: 20
Study 14982562 — intervention group
Group type: COMPARATOR
Intervention: Propofol 10 mg ml(-1)
Number of subjects: 20
Study 11354206 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lignocaine 0.1 ml via a 27 gauge needle and diabetic syringe before cannulation
Number of subjects: 322
Study 11354206 — intervention group
Group type: COMPARATOR
Intervention: Saline substituted for lignocaine
Number of subjects: 322
Study 11354206 — intervention group
Group type: COMPARATOR
Intervention: Immediate cannulation without local anaesthetic
Number of subjects: 322
Study 9149896 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-delivered, self-help intervention to reduce fat and increase fiber intake
Number of subjects: 1795
Study 9149896 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1795
Study 7536155 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 0.1 mg subcutaneously 120 and 30 min before EST and four hours after
Number of subjects: 151
Study 7536155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 7536155 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 151
Study 30121588 — intervention group
Group type: EXPERIMENTAL
Intervention: 5+ live births
Number of subjects: 40687
Study 30121588 — intervention group
Group type: COMPARATOR
Intervention: 0 prior pregnancies
Number of subjects: 40687
Study 30121588 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 prior pregnancy
Number of subjects: 40687
Study 30121588 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-4 prior pregnancies
Number of subjects: 40687
Study 30121588 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproductive Duration (RD)
Number of subjects: 40687
Study 27901556 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Universal retreatment (PTUR)
Number of subjects: 36
Study 27901556 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo R
Number of subjects: 36
Study 27901556 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐RaCe
Number of subjects: 36
Study 25404215 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message intervention (SMS sent at h48, D7, D15 and monthly)
Number of subjects: 0
Study 25404215 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (control group)
Number of subjects: 0
Study 25404215 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 0
Study 23740148 — intervention group
Group type: EXPERIMENTAL
Intervention: Early lactate normalization during the first 6 hours of resuscitation
Number of subjects: 187
Study 23740148 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate clearance ≥ 50%
Number of subjects: 187
Study 23740148 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate clearance ≥ 10%
Number of subjects: 187
Study 23740148 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial lactate level
Number of subjects: 187
Study 23740148 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative lactate clearance
Number of subjects: 187
Study 23740148 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate clearance rate
Number of subjects: 187
Study 23740148 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 187
Study 20886733 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial bitemporal magnetotherapy (TcMT) combined with reduced basic therapy (driptan 2.5 mg twice a day)
Number of subjects: 58
Study 20886733 — intervention group
Group type: COMPARATOR
Intervention: Placebo TcMT with basic therapy
Number of subjects: 58
Study 18997262 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed regularization-based algorithm for IMRT planning
Number of subjects: 2
Study 18997262 — intervention group
Group type: COMPARATOR
Intervention: Equal number of four segments for each field (control)
Number of subjects: 2
Study 16648332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 34
Study 16648332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 16648332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 34
Study 16648332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (N=14 overweight and obese subjects)
Number of subjects: 34
Study 16648332 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=14 overweight and obese subjects)
Number of subjects: 34
Study 12953327 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal patches releasing estradiol (E2) and progestogen for HRT
Number of subjects: 0
Study 12953327 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive patches delivering ethinyl E2 and norelgestromin
Number of subjects: 0
Study 12953327 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone patches for hypogonadal men
Number of subjects: 0
Study 12953327 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal delivery of reproductive steroids
Number of subjects: 0
Study 12953327 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal systems
Number of subjects: 0
Study 10811676 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan 1.25 mg/m(2)/d PO x 5 preceded by cisplatin 75 mg/m(2) IV day 1
Number of subjects: 49
Study 10811676 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan 2.0 mg/m(2)/d PO followed by cisplatin 75 mg/m(2) IV day 5
Number of subjects: 49
Study 10811676 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 75 mg/m(2) IV
Number of subjects: 49
Study 8800169 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous tepid cardioplegia
Number of subjects: 60
Study 8800169 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate tepid cardioplegia
Number of subjects: 60
Study 8800169 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 60
Study 8800169 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous cardioplegia
Number of subjects: 60
Study 1727803 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of insulin (30 IU) and glucagon (3 mg) for 12 hr/day during a 3-week period
Number of subjects: 72
Study 1727803 — intervention group
Group type: COMPARATOR
Intervention: Control group received an infusion of glucose for 12 hr/day during a 3-week period
Number of subjects: 72
Study 3977401 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk supplemented with human milk protein
Number of subjects: 35
Study 3977401 — intervention group
Group type: COMPARATOR
Intervention: Human milk alone
Number of subjects: 35
Study 29710797 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyeglasses voucher program (subsidy voucher redeemable for a free pair of prescription eyeglasses)
Number of subjects: 13100
Study 29710797 — intervention group
Group type: COMPARATOR
Intervention: No subsidy (control group)
Number of subjects: 13100
Study 27391911 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifeline ARM chest compression system (ARM; Defibtech)
Number of subjects: 37
Study 27391911 — intervention group
Group type: COMPARATOR
Intervention: Standard BLS (manual chest compressions)
Number of subjects: 37
Study 25244317 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia abutments (test)
Number of subjects: 38
Study 25244317 — intervention group
Group type: COMPARATOR
Intervention: Titanium abutments (control)
Number of subjects: 38
Study 25244317 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study 22453589 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc citrate 50 mg and phytase 3,000 PU
Number of subjects: 77
Study 22453589 — intervention group
Group type: COMPARATOR
Intervention: Lactulose placebo
Number of subjects: 77
Study 22453589 — intervention group
Group type: COMPARATOR
Intervention: Zinc gluconate 10 mg
Number of subjects: 77
Study 19536077 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved chimney stove
Number of subjects: 1047